Caseware UK (AP4) 2024.0.164 2024.0.164 2025-09-30 2025-09-30 true false sale of medical equipment 2024-10-01 0 true 0 08689983 2024-10-01 2025-09-30 08689983 2023-10-01 2024-09-30 08689983 2025-09-30 08689983 2024-09-30 08689983 c:Director1 2024-10-01 2025-09-30 08689983 d:CurrentFinancialInstruments 2025-09-30 08689983 d:CurrentFinancialInstruments 2024-09-30 08689983 d:CurrentFinancialInstruments d:WithinOneYear 2025-09-30 08689983 d:CurrentFinancialInstruments d:WithinOneYear 2024-09-30 08689983 d:ShareCapital 2025-09-30 08689983 d:ShareCapital 2024-09-30 08689983 d:RetainedEarningsAccumulatedLosses 2025-09-30 08689983 d:RetainedEarningsAccumulatedLosses 2024-09-30 08689983 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2025-09-30 08689983 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2024-09-30 08689983 c:OrdinaryShareClass1 2024-10-01 2025-09-30 08689983 c:OrdinaryShareClass1 2025-09-30 08689983 c:OrdinaryShareClass1 2024-09-30 08689983 c:EntityHasNeverTraded 2024-10-01 2025-09-30 08689983 c:FRS102 2024-10-01 2025-09-30 08689983 c:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 08689983 c:FullAccounts 2024-10-01 2025-09-30 08689983 c:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 08689983 2 2024-10-01 2025-09-30 08689983 e:PoundSterling 2024-10-01 2025-09-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 08689983 MEDICAL MANUFACTURERS EUROPE LIMITED UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025
MEDICAL MANUFACTURERS EUROPE LIMITED REGISTERED NUMBER: 08689983 BALANCE SHEET AS AT 30 SEPTEMBER 2025
|  | 2025 |  | 2024
Note |  | £ |  | £
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 4 | 100 |  | 100 |
Cash at bank and in hand | 5 | 421 |  | 559 |
|  | 521 |  | 659 |
Creditors: amounts falling due within one year | 6 | (144) |  | (138) |
Net current assets |  |  | 377 |  | 521
Total assets less current liabilities |  |  | 377 |  | 521
Net assets |  |  | 377 |  | 521
Capital and reserves |  |  |  |  |
Called up share capital | 8 |  | 100 |  | 100
Profit and loss account |  |  | 277 |  | 421
|  |  | 377 |  | 521
Page 1
MEDICAL MANUFACTURERS EUROPE LIMITED REGISTERED NUMBER: 08689983 BALANCE SHEET (CONTINUED) AS AT 30 SEPTEMBER 2025 For the year ended 30 September 2025 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006. Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 20 March 2026.
................................................ Richard Walmsley
Director
The notes on pages 3 to 5 form part of these financial statements. Page 2
MEDICAL MANUFACTURERS EUROPE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025
1. | General information
Medical Manufacturers Europe Limited is a company limited by shares and incorporated in England. The is dormant and did not trade during the year. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
| 2.2 | Interest income
Interest income is recognised in profit or loss using the effective interest method.
| 2.3 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.4 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
3. | Employees
| The Company has no employees other than the director, who did not receive any remuneration (2024 - £NIL).
4. | Debtors
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Called up share capital not paid | 100 | 100
|  | 100 | 100
Page 3
MEDICAL MANUFACTURERS EUROPE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025
5. | Cash and cash equivalents
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Cash at bank and in hand | 421 | 559
|  | 421 | 559
6. | Creditors: Amounts falling due within one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Accruals and deferred income | 144 | 138
|  | 144 | 138
Page 4
MEDICAL MANUFACTURERS EUROPE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025
7. | Financial instruments
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Financial assets |  |
| Financial assets measured at fair value through profit or loss | 421 | 559
| Financial assets measured at fair value through profit or loss comprise cash at bank.
8. | Share capital
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 100 (2024 - 100) Ordinary shares of £1.00 each | 100 | 100
9. | Controlling party
The company is controlled by Gordon Gardner Pty Ltd, an Australian based company, who owns all of the shares in the company.
Page 5